Skip to main content
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe
FR
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
  • Find Reports
    • Programs & Initiatives
      • Aging in Place
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Emergency Department Overcrowding
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
Canada’s Drug Agency | Drugs, Health Technologies and Systems.
FR
  • Find Reports
  • Our Work
    • Programs & Initiatives
      • Advisory Panel: Pan-Canadian Prescription Drug List
      • Aging in Place
      • Appropriate Use
      • Canadian Medical Imaging Inventory
      • Drugs for Rare Diseases
      • Emergency Department Overcrowding
      • Health Technology Reviews
      • Horizon Scans
      • Post-Market Drug Evaluation
      • Reimbursement Reviews
      • Scientific Advice
    • Methods
      • Conflict of Interest
      • Methodological Guidelines
      • Program Procedures
    • Tools & Publications
      • Common Acronyms
      • Evidence Bundles
      • HTA Excel Tools
      • Finding the Evidence: Literature Searching Tools in Support of Systematic Reviews
      • Canadian Journal of Health Technologies
  • Get Involved
    • Provide Input
      • Current Opportunities
      • Instructions
      • Procedures & Templates
    • Engage
      • Sponsor a Reimbursement Review
      • Request Scientific Advice
      • Request an Evidence Review
    • Community Involvement
      • Collaboration and Outreach
      • Patient Groups
      • Pan-Canadian Collaborative
  • About
  • News & Events
  • Careers
  • Contact
  • Subscribe

Dutasteride

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : August 24, 2004

Cinacalcet hydrochloride

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : August 20, 2004

Butoconazole nitrate

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : June 30, 2004

Eprosartan mesylate/ hydrochlorothiazide

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : July 8, 2004

Teriparatide (rDNA origin) injection

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : June 8, 2004

Ciprofloxacin hydrochloride and dexamethasone otic suspension

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : June 11, 2004

Peginterferon alfa-2a and Ribavirin

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : May 14, 2004

Miglustat

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : May 13, 2004

Mixed amphetamine salts

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : April 13, 2004

Pegfilgrastim

  • Reimbursement Reviews
    • About Reimbursement Reviews
    • Process Overview
    • Procedures, Templates, and Fee Schedule
    • Filing an Application
    • Clinician Input Instructions
    • Patient Input Instructions
    • Open Calls
    • Provisional Funding Algorithms
    • Pharmaceutical Review Update
    • Advisory Committees
    • Participating Drug Programs
    • Consultation on Proposed Improvements to the Reimbursement Review Process

Details

Last Updated : March 29, 2004

Pagination

  • Previous page ‹‹
  • Page 110
  • Next page ››

Canada’s Drug Agency is a pan-Canadian health organization, created and funded by Canada’s federal, provincial, and territorial governments.

We provide Canada’s health system leaders with independent evidence and advice so they can make informed drug, health technology, and health system decisions, and we collaborate with national and international partners to enhance our collective impact. 

  • Reports
  • Contact
  • Careers
  • Help

Stay up to date on the latest from Canada’s Drug Agency by subscribing to our newsletter.

Already subscribed? Update your preferences.

  • visit us on facebook
  • visit us on linkedin
  • visit us on youtube
  • visit us on instagram

© 2025 Canadian Agency for Drugs and Technologies in Health

  • Privacy Policy
  • Terms of Use
  • Accessibility
  • Request for Archived Report
Back to Top